Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics

Current cash is expected to support operations into the second half of 2029 as Processa advances its clinical pipeline.

Rhea-AI Summary

Processa Pharmaceuticals (PCSA) received FDA clearance to begin a Phase 2 study of VT-7208 in chronic spontaneous urticaria, following its Vidya acquisition. The planned randomized, double-blind, placebo-controlled trial is expected to enroll approximately 120 adults with moderate-to-severe disease inadequately controlled by H1 antihistamines. It will assess efficacy, safety, tolerability and pharmacologic activity over 12 weeks. Processa also plans Phase 2 studies in food allergy and relapsing multiple sclerosis.

The company entered a research collaboration and exclusive option agreement with Generian Pharmaceuticals for an oral neonatal Fc receptor antagonist program targeting autoimmune diseases. The Vidya acquisition was accompanied by an approximately $200 million private placement; Processa expects current cash to fund operations into the second half of 2029. Sheila Gujrathi was appointed Executive Chair.

6 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointApproximately $200 million private placement accompanied the Vidya acquisition. 39× market cap
• Major point. Forward-looking: it has not happened yet and may not happen.Current cash resources are expected to support operations into the second half of 2029.
• Moderate pointFDA clearance enables a Phase 2 VT-7208 study in adults with moderate-to-severe chronic spontaneous urticaria.
• Moderate pointGenerian research collaboration and exclusive option agreement expands the pipeline with an oral neonatal Fc receptor antagonist program.
• Minor point. Forward-looking: it has not happened yet and may not happen.Phase 2 CSU study is expected to enroll approximately 120 adults and evaluate treatment over 12 weeks.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional Phase 2 studies are planned for VT-7208 in food allergy and relapsing multiple sclerosis.

Negative

• None.

Argus 15 min delay 7 alerts

+2.98% vs previous close $1.91 last price 2.3x rel. volume Open Argus

Details

Market Reaction – PCSA

+5.0% Peak in 2 min

$1.53 – $1.95 Day Range

$5.32M Mkt Cap at Last Price

On Oct 29, the day this news came out, the latest delayed price for PCSA is 2.98% above the previous close. Argus tracked a peak move of +5.0% during the session. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $1.91. Relative volume is elevated at 2.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Private placement: Approximately $200 million Cash runway: Into the second half of 2029 Planned study enrollment: Approximately 120 adults +1 more

Private placement

Approximately $200 million

Funding accompanying the Vidya acquisition

Cash runway

Into the second half of 2029

Expected support for operations

Planned study enrollment

Approximately 120 adults

Phase 2 VT-7208 study in CSU

Study duration

12 weeks

VT-7208 versus placebo

Historical Context

1 past event · Latest: Jul 29

1 event

1. Jul 29

   Acquisition financing

   24h Move

   -33.4%

   Acquired Vidya and raised approximately $200 million to fund VT-7208 development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

investigational new drug (ind), chronic spontaneous urticaria, btk inhibitor, macrocyclic peptide, +1 more

5 terms

investigational new drug (ind) regulatory

"clearance of the investigational new drug (IND) application"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

chronic spontaneous urticaria medical

"Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU)"

A long-term condition that causes recurring, itchy hives and sometimes swelling that appear without a clear trigger, like an alarm that goes off unpredictably on its own. It matters to investors because its chronic nature creates ongoing demand for treatments, diagnostics and follow-on care, influencing pharmaceutical research priorities, drug market size, regulatory review timelines and healthcare cost projections.

btk inhibitor medical

"a Bruton's tyrosine kinase (BTK) inhibitor therapy"

A BTK inhibitor is a drug that blocks Bruton's tyrosine kinase, a protein that helps certain immune cells grow and communicate; by interrupting that signal it can reduce harmful immune activity or slow the growth of some blood cancers. For investors, BTK inhibitors matter because their clinical trial results, regulatory approvals, and market uptake can drive large, recurring sales or create competitive advantages for drugmakers, while failures or safety issues can sharply reduce a developer’s value—think of the drug as a targeted tool that can make or break a biotech’s prospects.

macrocyclic peptide medical

"a novel oral macrocyclic peptide-based neonatal Fc receptor"

A macrocyclic peptide is a molecule made of amino acids whose backbone or side chains are joined to form a large, covalent ring rather than an open chain. The ring locks the peptide into a constrained three-dimensional shape, which commonly increases resistance to enzymatic breakdown and can improve how tightly and selectively it binds biological targets; macrocyclization can be achieved by joining the peptide ends (head-to-tail), linking side chains, or inserting a non‑peptidic bridge.

neonatal fc receptor medical

"neonatal Fc receptor (FcRn) antagonist program"

A neonatal Fc receptor (FcRn) is a protein that acts like a recycling center for antibodies in the body, protecting them from breakdown and extending how long they stay active in the bloodstream. For investors, FcRn matters because drugs that target or use this pathway can change how often a therapy must be given, its effectiveness, and potential side effects—factors that influence market value, development costs, and competitive advantage in biologic and antibody-based treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis
  
  
• Company expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals
  
  
• Sheila Gujrathi, M.D., appointed Executive Chair of Processa’s Board of Directors
  
  
• Cash runway expected to fund operations into the second half of 2029
  
  

VERO BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced continued execution following its acquisition of Vidya Therapeutics (“Vidya”). Progress includes U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), expansion of the pipeline through a research collaboration with Generian Pharmaceuticals, and the appointment of Sheila Gujrathi, M.D., as Executive Chair of the Board of Directors.

Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase 2 proof-of-concept programs, including CSU, food allergy and relapsing multiple sclerosis. These programs provide multiple opportunities to evaluate VT-7208 across distinct immune-mediated diseases. The acquisition was accompanied by an approximately $200 million private placement from leading institutional healthcare investors. The Company expects its current cash resources to support operations into the second half of 2029.

“Since the Vidya transaction, we have made great progress in executing our strategy,” said Dr. Gujrathi. “The FDA clearance of the CSU IND is an exciting step toward advancing VT-7208 across three planned Phase 2 programs. At the same time, the Generian collaboration expands our pipeline around another high-value, clinically validated immune target. With funding in place to support these programs, our focus is on disciplined execution and generating the data needed to demonstrate the potential of the portfolio.”

“Sheila has been an invaluable partner to the Board since the Vidya transaction, and her experience building biotechnology companies, advancing clinical programs and creating long-term value makes her well suited to lead the Board through this next phase,” said Justin Yorke, former Chair of the Processa Board of Directors. “We are pleased to have her step into the Executive Chair role as Processa advances its clinical strategy and broader pipeline.”

FDA Clears IND for Phase 2 Study of VT-7208 in CSU

The FDA has cleared the IND application for VT-7208 in CSU, enabling Processa to advance the program into a Phase 2 study in adults with moderate-to-severe disease.

The planned multicenter, randomized, double-blind, placebo-controlled study is expected to enroll approximately 120 adults whose disease is not adequately controlled with H1 antihistamines. The study will evaluate VT-7208 versus placebo over 12 weeks and assess efficacy, safety, tolerability and pharmacologic activity.

CSU is a chronic inflammatory disease characterized by recurrent hives, swelling or both without an identifiable external trigger and affects an estimated 1.6 to 2 million U.S. adults. Despite available therapies, a meaningful proportion of patients remain inadequately controlled, underscoring the need for additional treatment options.

Pipeline Expansion Through Research Collaboration

Processa also announced that it has entered into a research collaboration and exclusive option agreement with Generian Pharmaceuticals, a UPMC Enterprises portfolio company that emerged from the UPMC/University of Pittsburgh ecosystem for breakthrough science, to advance a novel oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist program, further expanding Processa’s immunology pipeline.

The collaboration targets a clinically validated mechanism for treating IgG-mediated autoimmune diseases and supports the companies’ shared strategy of developing differentiated oral therapeutic alternatives to currently available injectable FcRn therapies. The program complements VT-7208 and reflects Processa’s broader strategy to selectively expand its pipeline around clinically validated immune targets, using capital-efficient structures that provide access to novel programs while preserving flexibility as the science matures.

Sheila Gujrathi Appointed Executive Chair

Dr. Gujrathi has been appointed Executive Chair of the Processa Board of Directors. She has served on the Board since Processa’s acquisition of Vidya in June 2026, where she was founder and its executive chair. In this expanded role, she will support the management team on corporate strategy, capital allocation and organizational development.

Dr. Gujrathi is a physician-scientist, biotechnology entrepreneur and drug developer with extensive experience building biotechnology companies and advancing therapies in immunology. Her prior leadership roles include Executive Chair of Ventyx Biosciences, Chair of Turning Point Therapeutics, Chair of ADARx Pharmaceuticals, co-founder and Chief Executive Officer of Gossamer Bio, and Chief Medical Officer of Receptos.

ABOUT PROCESSA PHARMACEUTICALS

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing innovative drug candidates through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. VT-7208 is a potentially best-in-class BTK inhibitor (BTKi) designed to improve on the efficacy and safety of early-generation programs. Processa is developing VT-7208 in three parallel programs: food allergy and chronic spontaneous urticaria (CSU) in immunology, and relapsing multiple sclerosis (RMS) in neurology, where its CNS-penetrant profile addresses an area of high unmet need. With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Processa, Vidya, the concurrent private placement financing and the acquisition of Vidya by Processa (the “Transactions”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect to the Transactions; expectations regarding or plans for VT-7208, including its planned clinical trials, research and development programs and the expected timing for key milestones; the potential benefits of VT-7208 and other clinical and preclinical programs; the perceived benefits of the research collaboration and exclusive option agreement with Generian Pharmaceuticals; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company into the second half of 2029. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transactions will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” and in the company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2026 , as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Processa, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

CONTACTS
Investors
Priyanka Shah
Elephant Head Communications
pshah@elephantheadcommunicationsllc.com

Media
Ryan Flinn
The Grace Group
ryan@gracegroup.us

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the FDA clear for Processa's VT-7208 program?

The FDA cleared the investigational new drug application, allowing Processa to advance VT-7208 into a Phase 2 study in chronic spontaneous urticaria. The planned trial will compare VT-7208 with placebo in approximately 120 adults whose moderate-to-severe disease is inadequately controlled with H1 antihistamines.

How long does Processa expect its cash to fund operations?

Processa expects its current cash resources to support operations into the second half of 2029. Its acquisition of Vidya was accompanied by an approximately $200 million private placement from institutional healthcare investors.

What will Sheila Gujrathi do as Processa's Executive Chair?

Sheila Gujrathi will support management on corporate strategy, capital allocation and organizational development as Executive Chair. She has served on Processa's board since the acquisition of Vidya in June 2026.